Northwest Biotherapeutics Inc NWBO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.15
- Day Range
- $0.15–0.16
- 52-Week Range
- $0.14–0.33
- Bid/Ask
- $0.10 / $0.81
- Shares Outstanding
- 1.71B
- Market Cap
- $246.97M
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 109.72
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 105
- Website
- https://www.nwbio.com
Valuation
|
Metric
|
NWBO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 109.72 |
Price/Cash Flow | — |
Price/Earnings
NWBO
Financial Strength
|
Metric
|
NWBO
|
|---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.04 |
Interest Coverage | −3.06 |
Quick Ratio
NWBO
Profitability
|
Metric
|
NWBO
|
|---|---|
Return on Assets (Normalized) | −109.69% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NWBO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^fkhfFw | LOCK|Mg<p | $128B | |||
| Moderna Inc
MRNA
| LOCK|y$pY%d# | LOCK|nsJ | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<<SnYk | LOCK|jCY% | $76B | |||
| argenx SE ADR
ARGX
| LOCK|Mwby<? | LOCK|QK | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|KM?w^kd | LOCK|@m | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|h^QZ#gs | LOCK|S?#@ | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&>Rvk>^ | LOCK|><ml | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|q^#K&X | LOCK|&@ | $24B | |||
| Incyte Corp
INCY
| LOCK|L&m^<% | LOCK|%g! | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$k?jh!% | LOCK|!d! | $15B |
United States